LuciVemu — Vemurafenib 240 mg, 56 pcs, Lucius

LuciVemu — Vemurafenib Tablets 240 mg, 56 Tablets

Product code: 520

20115₴ 21948₴ -8% On order · from 10 days

Analogues

LuciVemu Zelboraf
1
Active ingredient
Dosage
240 mg
Dosage form Tablets
Tablets per pack 56

LuciVemu is a targeted antineoplastic agent belonging to the protein kinase inhibitor class, indicated for the treatment of unresectable or metastatic melanoma harboring BRAF V600 mutations. The active pharmaceutical ingredient is vemurafenib at a strength of 240 mg supplied as film-coated oral tablets (Vemurafenib Tablets 240 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Vemurafenib is an oral selective inhibitor of the serine-threonine kinase BRAF. Mutations in the BRAF gene (specifically the valine to glutamic acid substitution at codon 600 — V600E) result in constitutive activation of the MAPK/ERK signaling pathway, driving uncontrolled melanoma tumor growth. Vemurafenib specifically blocks this activated mutant kinase, halting tumor proliferation and inducing cancer cell apoptosis.

Supplied in a package containing 56 tablets of 240 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciVemu 240 mg:

  • ✅ Selective BRAF V600 Inhibition: High selectivity for mutant BRAF forms (V600E and V600K).
  • ✅ Proven Clinical Efficacy: Significant survival prolongation and tumor reduction in metastatic melanoma patients.
  • ✅ Convenient Oral Dosing: Taken orally twice daily.
  • ✅ Optimal Strength: 240 mg tablets enable precise compliance with cyclic treatment regimens.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Zelboraf).

LuciVemu is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Vemurafenib — 240 mg.
  • Excipients: Croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, hydroxypropyl cellulose. Coating: hypromellose, iron oxide red, titanium dioxide, macrogol.

Packaging and Presentation: Film-coated tablets, 240 mg strength. Each package contains 56 tablets along with prescribing information. Labeled with LuciVemu (Vemurafenib Tablets 240 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Vemurafenib is a low-molecular-weight oral inhibitor of mutant BRAF serine-threonine kinases. BRAF gene mutations lead to constitutive activation of the kinase domain, triggering tumor growth. Vemurafenib suppresses BRAF kinase activity with V600 mutations (including V600E, V600K, etc.), blocking signaling in melanoma tumor cells and inhibiting division.

Pharmacokinetics:

  • Absorption: Following oral administration, vemurafenib is absorbed; peak plasma concentration (Tmax) is achieved within approximately 3 to 4 hours. Food intake (especially high-fat meals) significantly increases drug bioavailability.
  • Distribution: Human plasma protein binding is very high (exceeding 99%).
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 enzyme of the cytochrome P450 system.
  • Elimination: Excreted predominantly via feces (approx. 94% as metabolites and unchanged drug) and renally (less than 1%). Terminal elimination half-life (T1/2) averages approximately 51.6 hours.

LuciVemu is indicated in adult patients for (in the presence of confirmed BRAF V600 mutations):

  • Melanoma: Treatment of adult patients with unresectable or metastatic melanoma with a positive BRAF V600 mutation (detected by a validated test).

LuciVemu is administered orally twice daily every day (morning and evening) approximately 12 hours apart.

Dosing Regimen:
The recommended standard dose is 960 mg (four 240 mg tablets) twice daily (total daily dose of 1920 mg, corresponding to eight 240 mg tablets per day). Continue treatment until disease progression or unacceptable toxicity occurs.

Administration Guidelines:
Tablets should be swallowed whole with water; do not break, crush, or chew. Can be taken with or without food, though regular intake with high-fat meals should be avoided. If a dose is missed, it can be taken unless fewer than 4 hours remain before the next scheduled dose.

Administration of LuciVemu is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to vemurafenib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced dysfunction (requiring extreme caution).

Vemurafenib is a substrate and inhibitor/inducer of certain cytochrome P450 enzymes:

  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease vemurafenib plasma concentrations and reduce efficacy (avoid concurrent use).
  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): May elevate vemurafenib exposure.
  • QT-Prolonging Drugs: Co-administration requires rigorous ECG monitoring due to arrhythmia risks.

Pregnancy:
LuciVemu is contraindicated during pregnancy. Based on its mechanism of action, vemurafenib may cause fetal harm and embryotoxicity. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 2 months following the final dose.

Lactation:
Excretion of vemurafenib into human breast milk is unstudied, though potential risk to the child cannot be ruled out. Breastfeeding must be discontinued during treatment and for 2 weeks post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions (Very Common): Cutaneous squamous cell carcinoma, keratoacanthoma, rash, pruritus, photosensitivity, hyperkeratosis, dry skin.
  • Gastrointestinal Tract: Nausea, diarrhea, vomiting, constipation, decreased appetite.
  • Musculoskeletal System: Arthralgia, myalgia, pain in extremities.
  • General Disorders: Fatigue, asthenia, headache, peripheral edema, pyrexia.
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST, alkaline phosphatase), QT interval prolongation on ECG.

Symptoms:
Specific acute overdose symptoms of vemurafenib are unestablished. Administration at doses exceeding recommended levels resulted in exacerbated adverse reactions (skin and joint toxicities).

Treatment:
No specific antidote exists. In case of overdose, temporarily withhold treatment and initiate supportive and symptomatic care under medical observation.

Storage Requirements for LuciVemu 240 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciVemu 240 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Vemurafenib Tablets 240 mg, and 56 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00